DRG Abacus’ Clinical Outcomes Assessment (COA) team regularly conduct qualitative research throughout the drug development process to better understand how diseases and/or products affect patients and caregivers.
The most common method for eliciting qualitative data undertaken by the COA team is through interviews with patients, caregivers, or clinicians, either in person, via telephone or using web-based software. We sometimes conduct focus groups (qualitative research with a group of participants) which can be more suitable for certain diseases and patient groups. However, we will work with you to select the best approach for data capture depending upon the population of interest, project requirements, timelines, and budget.
For identification of potentially suitable COA measures, and to inform endpoint selection in clinical trials, qualitative research is required to ensure the concept(s) captured are important to patients and their caregivers (where relevant). By not undertaking qualitative research in this early phase, it is difficult to understand whether the data being collected is relevant to the patient group.
DRG Abacus’ COA team can conduct qualitative research to help answer numerous product and trial related questions:
At DRG Abacus we understand the importance of robust qualitative research to inform your PRO/COA strategy.
We are part of Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd.
DRG offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1,000 employees across 17 offices in North America, Europe and Asia.Our Company